Table 1 Patient Characteristics
Cohort characteristics | Orofacial symptomatic group at T0 | Orofacial asymptomatic group at T0 |
|---|---|---|
Number | 62 | 51 |
Mean age at baseline, years (sd) | 14.6 (2.9) | 13.9 (2.4) |
JIA subcategories, number | ||
Oligoarticular extended | 4 | 1 |
Oligoarticular persistent | 26 | 28 |
Polyarticular | 27 | 17 |
Systemic | 1 | 1 |
Psoriatic | 3 | 4 |
Enthesitis related arthritis | 0 | 0 |
Unknown | 1 | 0 |
Disease duration | ||
Mean years (sd) | 7.4 (4.2) | 6.6 (4.4) |
< 1 years | 0 | 1 |
0–3 | 5 | 6 |
> 3 | 57 | 44 |
TMJ-specific treatment in the follow-up period, number | ||
Flat splint (night) | 12 | 5 |
Flat splint (full time) | 10 | 0 |
Distraction splint | 4 | 6 |
Full fixed appliances | 5 | 4 |
Previous full fixed appliances | 12 | 9 |
Surgical osseous distraction | 1 | 0 |
Activator | 4 | 3 |
Intra articular TMJ steroid | 3 | 0 |
Orofacial physiotherapy | 8 | 0 |
Home Exercises | 4 | 0 |
No treatment | 12 | 25 |
Medical treatment in the follow-up period, number | ||
NSAID | 19 | 4 |
Methotrexate | 27 | 16 |
Leflunomide | 4 | 0 |
Systemic steroid | 1 | 0 |
Biologics | 26 | 16 |
No medication | 36 | 38 |
Combination of two drugs | 19 | 6 |
Combination of three drugs | 3 | 1 |
Change in treatment during follow-up | 21 | 15 |